Latest news on Alzheimer's
Check out the latest news about Alzheimer's disease research that we carry out at the Barcelonaβeta Brain Research Center (BBRC). Discover the advances in Alzheimer's prevention in which our scientists participate, as well as the news of the Alfa Study, dedicated to the early detection and prevention of the disease.
A blood test for early detection of Alzheimer's disease
A study involving more than 1,700 people from five hospitals in Barcelona, Sweden and Italy has validated the usefulness of a biomarker in blood to detect Alzheimer's disease in the clinical setting.
We participate once again in the AD/PD 2025
BBRC researchers share key advances in Alzheimer's and neurosciences in the framework of the AD/PD 2025.
The EMA issues a negative opinion on the authorization of donanemab for the treatment of Alzheimer's disease
Donanemab, approved in the US and other countries, fails to get approval in Europe due to concerns about its adverse effects
Study reveals gender inequalities in participation in clinical trials for Alzheimer’s disease prevention
The study highlights the need to adapt recruitment strategies to existing gender differences to ensure equitable representation in research.
New study compares plasma biomarkers for detecting Alzheimer’s disease in memory clinics
The findings revealed that plasma p-tau biomarkers demonstrated superior accuracy in detecting Alzheimer’s compared to other biomarkers
We received a visit from Alzheimer's Research UK
With the strategic objective of establishing synergies in research, advocacy and fundraising, among other areas
The BBRC receives financing from EBRAINS to streamline the use of data applied to neuroscience
The ALFA+EBRAINS project will facilitate access to key data for neurodegenerative disease research.
BBRC's outstanding participation in HACK'a'BRAIN, the first creative hackathon of the Brain Film Festival
BBRC researchers have mentored five scientific dissemination projects based on three current research lines
The BBRC participates in the ReTain study to evaluate a new pharmacological therapy for preclinical Alzheimer's
The goal of the study is to investigate the effect of this therapy on cognitive decline
